AtriCure reports preliminary Q4 revenue $140.5M (+13%), FY 2025 $534.5M (+15%); guides 2026 revenue ~$600-610M

AtriCure, Inc.

2025-FY EPS reported -$0.24 revenue$534,528,000

Q4 2025 revenue $140.5M (+13% YoY); US $114.3M (+13%), intl $26.2M (+15% as reported).
FY 2025 revenue $534.5M (+15% YoY); adj. EBITDA $57-59M; adj. loss per share $0.18-0.21.
Ended 2025 with $167M cash; expects positive cash flow and net income in 2026.
2026 revenue guidance $600-610M (+12-14%); adj. EBITDA $80-82M.
Amended credit facility extended 3 years, reduced interest rate, removed minimum utilization covenant.

item 1.01 item 2.02 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AtriCure, Inc. amended First Amendment to Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, bookrunner and lead arranger, and the lenders party thereto (effective 2026-01-09).

Action: amendment
Agreement: credit facility
Counterparty: JPMorgan Chase Bank, N.A., as administrative agent, bookrunner and lead arranger, and the lenders party thereto
Effective: 2026-01-09

Exact text from the filing

On January 9, 2026 (the “ Closing Date ”), AtriCure, Inc. (the “ Company ”) and its wholly owned subsidiary, AtriCure, LLC (together with the Company, the “ Borrowers ”), entered into a First Amendment (“ First Amendment ”) to Credit Agreement (as amended, the “ Credit Agreement ”) among the Borrowers, JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “ Administrative Agent ”), JPMorgan Chase Bank, N.A., as bookrunner and lead arranger (“ JPMCB ”), and the lenders party thereto (“ Lenders ”).

View on SEC.gov

Browse all material agreements →

AtriCure, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-009814

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.